You are here:
09 February 2021 / deal

Morgan Stanley, BofA Securities, and SVB Leerink act as joint book-running managers in connection with the IPO of Pharvaris on NASDAQ

Loyens & Loeff N.V. trad op als Nederlandse counsel voor Morgan Stanley, BofA Securities, en SVB Leerink, die optraden als joint book-running managers van de aanbieding. Oppenheimer & Co. en Kempen & Co traden op als co-managers.

Pharvaris N.V. (“Pharvaris”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, on 4 February 2021 announced the pricing of its upsized initial public offering of 8,270,500 of its ordinary shares at an initial public offering price of $20.00 per share, for total gross proceeds of approximately $165.4 million.

In addition, Pharvaris has granted the underwriters a 30-day over-allotment option to purchase up to an additional 1,240,575 ordinary shares at the public offering price less underwriting discounts and commissions. This over-allotment option was exercised on 5 February 2021 in full. The ordinary shares are expected to begin trading on the Nasdaq Global Select Market on 8 February 2021 under the symbol "PHVS."



IFLR Awards 2021 Europe

IFLR Europe 2021 Award “Debt and Equity-Linked Deal of the Year”

Loyens & Loeff won for advising Novartis with the offering of EUR 1.85 billion 0.000% Sustainability-Linked Notes due 2028. read more
Due Diligence For Swiss CBD Companies

Due Diligence for Swiss CBD Companies

Switzerland has proven to provide for attractive conditions for businesses involved in the production and distribution of cannabidiol (CBD) products. read more
Loyens & Loeff advised a private investor on the economic acquisition of Credit Suisse's real estate leasing portfolio

Economic acquisition of Credit Suisse

Loyens & Loeff advised a private investor on the economic acquisition of Credit Suisse's real estate leasing portfolio. read more